KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Gains from Sales and Divestitures (2019 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 29.84% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 29.84% year-over-year, with the annual reading at $3.4 million for FY2025, 29.84% up from the prior year.
  • Gains from Sales and Divestitures hit $3.4 million in Q4 2025 for Adaptive Biotechnologies, up from $3.2 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $3.4 million in Q4 2025 to a low of $12500.0 in Q2 2021.
  • Historically, Gains from Sales and Divestitures has averaged $1.3 million across 5 years, with a median of $1.2 million in 2023.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 1524.73% in 2022 and later crashed 89.04% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $18750.0 in 2021, then surged by 1524.73% to $304637.0 in 2022, then surged by 394.64% to $1.5 million in 2023, then soared by 71.73% to $2.6 million in 2024, then rose by 29.84% to $3.4 million in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for ADPT at $3.4 million in Q4 2025, $3.2 million in Q3 2025, and $3.1 million in Q2 2025.